Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer

OBJECTIVES: Treatments for advanced small‐cell lung cancer (SCLC) patients who are resistant to first‐line chemotherapy are limited. Given that antiangiogenic agents and immune‐checkpoint inhibitors (ICIs) can confer synergistic therapeutic benefits, combination therapy should be considered. We expl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lian, Xu, Jianlin, Qiao, Rong, Han, Baohui, Zhong, Hua, Zhong, Runbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028028/
https://www.ncbi.nlm.nih.gov/pubmed/36250532
http://dx.doi.org/10.1002/cam4.5360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028028/
https://www.ncbi.nlm.nih.gov/pubmed/36250532
http://dx.doi.org/10.1002/cam4.5360

Ejemplares similares